Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

Study Identifier
M03-598
CT.gov Identifier
NCT00234858
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hypertension & Blood Pressure
  • Endocrine - Other
    • Study Drug
  • trandolapril/verapamil
  • (Hyzaar) losartan/hydrochlorothiazide
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    21+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Metabolic syndrome - Fasting blood glucose between 100 mg/dL and 125 mg/dL - Hypertension - One additional criteria, Exclusion 1
    Exclusion Criteria:
    - Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus. - Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.

    Protocol Summary

    The primary objective of this study is to determine whether impaired glucose tolerance is

    improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

    Study Locations

    No locations found.